Many employers are unknowingly amassing drug rebate cash that’s funded by their sickest employees, in accordance with Mark Cuban.
Throughout Forbes’ Healthcare Summit final week in New York Metropolis, Cuban famous that People are sometimes paying full checklist costs throughout their deductible durations, successfully subsidizing the rebates that move again to pharmacy profit managers and employers. This can be a dynamic he argues most CEOs don’t absolutely perceive.
Cuban pointed to a standard state of affairs: an worker enrolled in a high-deductible well being plan receives a prescription for a brand-name drug like Eliquis, which might retail round $600 a month. Till the worker meets their deductible, they should pay that full checklist worth — even when the PBM has negotiated a considerable rebate on the drug.
That rebate, which might quantity to a whole bunch of {dollars} per prescription, by no means makes its method again to the affected person footing the invoice. As an alternative, the cash goes by means of the PBM and finally again to the employer, Cuban defined.
To him, this construction flips the intent of rebates on its head. Reasonably than decreasing prices for the individuals who want the remedy, this method finally ends up utilizing these sufferers’ excessive out-of-pocket funds to generate rebate checks that profit their employer. Cuban warned that by benefiting from rebates funded by sick employees, corporations may very well be falling wanting their obligation to behave in workers’ finest pursuits beneath the Worker Retirement Earnings Safety Act.
He highlighted direct-to-employer drug buying fashions as a approach to keep away from this problem.
His firm, Cost Plus Drugs, is creating direct-to-employer drug applications designed to bypass PBMs and safe web pricing. This manner, workers aren’t subsidizing rebates with their very own medical payments, Cuban said.
“I sit with the CEO, and I say, ‘Look, you’re getting ripped off by your PBM. And I perceive it’s troublesome to simply transfer, however there are a rising variety of direct-to-employer applications which are being created,’” he remarked.
Considered one of Price Plus Drug’s companions for its direct-to-employer drug pricing mannequin is CenterWell, Humana’s healthcare providers model.
Humana CEO James Rechtin famous that CenterWell desires to simplify its drug provide chain to ship medicines extra effectively and transparently. The corporate is doing extra contracting instantly with producers so shoppers and employers can see the true web value of medication and eschew the layers of intermediaries that drive up costs.
“With pharmacy, we principally regarded on the conventional mannequin, and we stated, ‘We aren’t getting the fee effectivity, the affordability, that we have to to guarantee that our members are having access to medicines,’” he stated.
If efforts to remove the middlemen proceed to scale, employees might save billions in out-of-pocket prices, Rechtin and Cuban agreed.
Photograph: mathisworks, Getty Pictures
